ES2719223T3 - Tratamiento de la vaginitis - Google Patents
Tratamiento de la vaginitis Download PDFInfo
- Publication number
- ES2719223T3 ES2719223T3 ES16455004T ES16455004T ES2719223T3 ES 2719223 T3 ES2719223 T3 ES 2719223T3 ES 16455004 T ES16455004 T ES 16455004T ES 16455004 T ES16455004 T ES 16455004T ES 2719223 T3 ES2719223 T3 ES 2719223T3
- Authority
- ES
- Spain
- Prior art keywords
- cultures
- test
- vaginal
- zeolite
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010046914 Vaginal infection Diseases 0.000 title description 7
- 201000008100 Vaginitis Diseases 0.000 title description 5
- 239000002245 particle Substances 0.000 claims abstract description 17
- 244000005700 microbiome Species 0.000 claims abstract description 13
- JYIBXUUINYLWLR-UHFFFAOYSA-N aluminum;calcium;potassium;silicon;sodium;trihydrate Chemical compound O.O.O.[Na].[Al].[Si].[K].[Ca] JYIBXUUINYLWLR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910001603 clinoptilolite Inorganic materials 0.000 claims abstract description 12
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims abstract description 9
- 208000037009 Vaginitis bacterial Diseases 0.000 claims abstract description 9
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 208000005448 Trichomonas Infections Diseases 0.000 claims abstract description 3
- 206010044620 Trichomoniasis Diseases 0.000 claims abstract description 3
- 208000013464 vaginal disease Diseases 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 53
- 239000000126 substance Substances 0.000 claims description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000000003 vaginal tablet Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- -1 ovule Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940044977 vaginal tablet Drugs 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 91
- 229910021536 Zeolite Inorganic materials 0.000 description 88
- 239000010457 zeolite Substances 0.000 description 88
- 238000012360 testing method Methods 0.000 description 80
- 230000012010 growth Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 25
- 241000207201 Gardnerella vaginalis Species 0.000 description 24
- 241000218492 Lactobacillus crispatus Species 0.000 description 22
- 238000011534 incubation Methods 0.000 description 19
- 239000002609 medium Substances 0.000 description 17
- 230000002503 metabolic effect Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 244000052616 bacterial pathogen Species 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 241000222122 Candida albicans Species 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 229940095731 candida albicans Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 10
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 10
- 241001561398 Lactobacillus jensenii Species 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000222173 Candida parapsilosis Species 0.000 description 7
- 229940055022 candida parapsilosis Drugs 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 4
- 239000011362 coarse particle Substances 0.000 description 4
- 230000009422 growth inhibiting effect Effects 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000222126 [Candida] glabrata Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000032343 candida glabrata infection Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000197813 Camelina sativa Species 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 206010073931 Genital herpes simplex Diseases 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000000522 vaginal cream Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 241001633064 Atopobium vaginae Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 208000008371 Bunyaviridae Infections Diseases 0.000 description 1
- 208000008889 California Encephalitis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 208000004293 Chikungunya Fever Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241001535083 Dialister Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000019645 Hemorrhagic fever-renal syndrome Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 241000203736 Mobiluncus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 201000006968 Oropouche fever Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 201000009754 Powassan encephalitis Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000538730 Rocio Species 0.000 description 1
- 201000007009 Ross river fever Diseases 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007954 growth retardant Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940044959 vaginal cream Drugs 0.000 description 1
- 244000000072 vaginal pathogen Species 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194288.5A EP3167890A1 (de) | 2015-11-12 | 2015-11-12 | Behandlung von vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2719223T3 true ES2719223T3 (es) | 2019-07-09 |
Family
ID=54542054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16455004T Active ES2719223T3 (es) | 2015-11-12 | 2016-10-25 | Tratamiento de la vaginitis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170136060A1 (https=) |
| EP (2) | EP3167890A1 (https=) |
| JP (1) | JP6792420B2 (https=) |
| KR (1) | KR102335607B1 (https=) |
| CN (1) | CN106974932B (https=) |
| AU (1) | AU2016247097B2 (https=) |
| CA (1) | CA2947570C (https=) |
| ES (1) | ES2719223T3 (https=) |
| TR (1) | TR201904382T4 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3524055A1 (de) * | 2018-02-08 | 2019-08-14 | BCSK Biocid GmbH | Antibakterielles und spermizides gleitmittel |
| US20230407365A1 (en) * | 2022-06-21 | 2023-12-21 | Pamela Miles | Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies |
| CN116059177A (zh) * | 2022-12-14 | 2023-05-05 | 迪沙药业集团有限公司 | 一种克林霉素磷酸酯组合物及其制备方法 |
| CN117535208B (zh) * | 2024-01-04 | 2024-03-29 | 四川厌氧生物科技有限责任公司 | 一种卷曲乳杆菌及其在女性生殖道健康中的应用 |
| JP7813333B1 (ja) * | 2024-11-08 | 2026-02-12 | 日本食品化工株式会社 | 膣常在菌叢バランス改善剤及び膣用組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6353146B1 (en) * | 1998-04-20 | 2002-03-05 | Playtex Products, Inc. | Fibrous articles having odor adsorbtion ability and method of making same |
| ES2165139T3 (es) * | 1998-04-30 | 2002-03-01 | Vesely Renata Maria Cavaliere | Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales. |
| EP1316530B1 (de) * | 1999-04-26 | 2004-12-15 | Tihomir Lelas | Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel |
| KR20060128125A (ko) * | 2005-06-09 | 2006-12-14 | 인하대학교 산학협력단 | 만델산을 유효성분으로 함유하는 질염 치료제 |
| WO2007054085A2 (de) * | 2005-11-11 | 2007-05-18 | Ljubicic, Mijo | Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum |
| SI2040837T1 (sl) | 2006-07-04 | 2012-10-30 | Gaston Glock | Postopek za odločenje težkih kovin |
| CN101594888A (zh) * | 2006-12-15 | 2009-12-02 | 欧兰益生公司 | 含有产乳酸细菌的吸收制品 |
| WO2009133413A1 (en) * | 2008-04-28 | 2009-11-05 | Novatech D.O.O. | Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism |
| EP2358642B2 (de) * | 2008-11-21 | 2022-12-07 | Froximun AG | Klinoptilolith oder klinoptilolithhaltige gemische |
| KR101198572B1 (ko) * | 2010-07-09 | 2012-11-06 | 경희대학교 산학협력단 | 미생물 감염증 치료 또는 개선용 조성물 |
-
2015
- 2015-11-12 EP EP15194288.5A patent/EP3167890A1/de not_active Withdrawn
-
2016
- 2016-10-19 AU AU2016247097A patent/AU2016247097B2/en not_active Ceased
- 2016-10-25 EP EP16455004.8A patent/EP3167891B1/de active Active
- 2016-10-25 ES ES16455004T patent/ES2719223T3/es active Active
- 2016-10-25 TR TR2019/04382T patent/TR201904382T4/tr unknown
- 2016-11-03 CA CA2947570A patent/CA2947570C/en active Active
- 2016-11-11 CN CN201610997927.6A patent/CN106974932B/zh active Active
- 2016-11-11 US US15/349,727 patent/US20170136060A1/en not_active Abandoned
- 2016-11-11 JP JP2016220187A patent/JP6792420B2/ja not_active Expired - Fee Related
- 2016-11-14 KR KR1020160151167A patent/KR102335607B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3167891A1 (de) | 2017-05-17 |
| CN106974932A (zh) | 2017-07-25 |
| EP3167890A1 (de) | 2017-05-17 |
| TR201904382T4 (tr) | 2019-04-22 |
| BR102016026252A2 (pt) | 2017-05-23 |
| JP2017088603A (ja) | 2017-05-25 |
| CA2947570C (en) | 2021-08-10 |
| CN106974932B (zh) | 2021-05-04 |
| US20170136060A1 (en) | 2017-05-18 |
| JP6792420B2 (ja) | 2020-11-25 |
| AU2016247097B2 (en) | 2021-12-02 |
| KR102335607B1 (ko) | 2021-12-06 |
| EP3167891B1 (de) | 2019-01-23 |
| KR20170055932A (ko) | 2017-05-22 |
| AU2016247097A1 (en) | 2017-06-01 |
| CA2947570A1 (en) | 2017-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2719223T3 (es) | Tratamiento de la vaginitis | |
| Matsubara et al. | Probiotics as antifungals in mucosal candidiasis | |
| Vicariotto et al. | Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study | |
| Das et al. | Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics | |
| ES2647833T3 (es) | Nueva cepa de Lactobacillus crispatus | |
| US10946049B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| US11083761B2 (en) | High potency stable formulations of vaginal Lactobacillus | |
| Joo et al. | Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation | |
| CN105555284A (zh) | 作为益生菌的戊糖乳杆菌菌株 | |
| US11730777B2 (en) | Mucoadhesive sustained-release vaginal tablet | |
| CN104519892A (zh) | 硫代硫酸盐加强乳杆菌的抗病原性效果的用途 | |
| Pashayan et al. | Development of bifunctional vaginal suppositories by joint use terconazole and probiotic for treatment and prophylaxis of vulvovaginal candidiasis | |
| KR20210042107A (ko) | 아토피 피부염을 치료하기 위한 그람 음성 종의 용도 | |
| AU2015237234A1 (en) | Preparation of small colony variants of therapeutic bacteria | |
| CN110225759A (zh) | 用于治疗皮肤和粘膜上的皮肤真菌病和酵母感染的具有活真菌寄生微生物寡雄腐霉(Pythium oligandrum)的制剂、测定微生物寡雄腐霉的细胞活力的方法以及施用该制剂的方法 | |
| BR102016026252B1 (pt) | Uso de clinoptilolita no tratamento de vaginite | |
| Fatima et al. | Antimicrobial Activity of Saccharomyces cerevisiae against Candida spp. Associated to Vulvovaginal Candidiasis | |
| Mohamed | The effect of a combination therapy of Fluconazole and Amphotericin B on the growth and CDR1 gene expression of Candida glabrata | |
| Fisher | A study at the Brooklyn Chest Hospital to assess the change in the oral carriage of Candida species in patients co-infected with HIV and TB, before and after antifungal therapy | |
| Oladele et al. | Prevalence of multi-drug resistant pathogen isolated from high vaginal swab in Nigeria | |
| Brayton | An in-vitro model for characterization of Fluoroquinolone antimicrobial Transport by Oral Epithelium | |
| CN103845729A (zh) | 胰蛋白酶的用途 | |
| HK1207116B (en) | Novel strain of lactobacillus crispatus |